SI1982708T1 - Terapevtsko sredstvo za vnetno črevesno bolezen, ki obsega 2-amino-1,3-propandiolni derivat kot učinkovino, in postopek za zdravljenje vnetne črevesne bolezni - Google Patents

Terapevtsko sredstvo za vnetno črevesno bolezen, ki obsega 2-amino-1,3-propandiolni derivat kot učinkovino, in postopek za zdravljenje vnetne črevesne bolezni

Info

Publication number
SI1982708T1
SI1982708T1 SI200731574T SI200731574T SI1982708T1 SI 1982708 T1 SI1982708 T1 SI 1982708T1 SI 200731574 T SI200731574 T SI 200731574T SI 200731574 T SI200731574 T SI 200731574T SI 1982708 T1 SI1982708 T1 SI 1982708T1
Authority
SI
Slovenia
Prior art keywords
inflammatory bowel
bowel disease
propanaediol
derivative
amino
Prior art date
Application number
SI200731574T
Other languages
English (en)
Inventor
Ryotaro Kojima
Koichi Nakamaru
Tokutarou Yasue
Original Assignee
Kyorin Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38345101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1982708(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyorin Pharmaceutical Co., Ltd. filed Critical Kyorin Pharmaceutical Co., Ltd.
Publication of SI1982708T1 publication Critical patent/SI1982708T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200731574T 2006-02-06 2007-02-05 Terapevtsko sredstvo za vnetno črevesno bolezen, ki obsega 2-amino-1,3-propandiolni derivat kot učinkovino, in postopek za zdravljenje vnetne črevesne bolezni SI1982708T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006027883 2006-02-06
PCT/JP2007/051887 WO2007091501A1 (ja) 2006-02-06 2007-02-05 ２－アミノ－１，３－プロパンジオール誘導体を有効成分とする炎症性腸疾患治療剤又は炎症性腸疾患の治療方法
EP07713815.4A EP1982708B1 (en) 2006-02-06 2007-02-05 Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3-propanaediol derivative as active ingredient, and method for treatment of inflammatory bowel disease

Publications (1)

Publication Number Publication Date
SI1982708T1 true SI1982708T1 (sl) 2015-01-30

Family

ID=38345101

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731574T SI1982708T1 (sl) 2006-02-06 2007-02-05 Terapevtsko sredstvo za vnetno črevesno bolezen, ki obsega 2-amino-1,3-propandiolni derivat kot učinkovino, in postopek za zdravljenje vnetne črevesne bolezni

Country Status (30)

Country Link
US (1) US8318811B2 (sl)
EP (2) EP1982708B1 (sl)
JP (1) JP5042042B2 (sl)
KR (1) KR101334153B1 (sl)
CN (1) CN101378743B (sl)
AU (1) AU2007213194B9 (sl)
BR (1) BRPI0706971A2 (sl)
CA (1) CA2641546C (sl)
CY (1) CY1116112T1 (sl)
DK (1) DK1982708T3 (sl)
EC (1) ECSP088662A (sl)
ES (1) ES2524056T3 (sl)
GT (1) GT200800148A (sl)
HK (1) HK1126119A1 (sl)
HR (1) HRP20080421B1 (sl)
IL (1) IL192150A (sl)
MA (1) MA31338B1 (sl)
MX (1) MX2008008872A (sl)
MY (1) MY151193A (sl)
NO (1) NO20082708L (sl)
NZ (1) NZ568907A (sl)
PL (1) PL1982708T3 (sl)
PT (1) PT1982708E (sl)
RU (1) RU2428976C2 (sl)
SG (1) SG169370A1 (sl)
SI (1) SI1982708T1 (sl)
TN (1) TNSN08246A1 (sl)
TW (1) TWI389683B (sl)
WO (1) WO2007091501A1 (sl)
ZA (1) ZA200806199B (sl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1772145T3 (pl) 2004-07-16 2011-08-31 Kyorin Seiyaku Kk Sposób skutecznego stosowania leku i sposób dotyczący zapobiegania efektom ubocznym
PT2511262T (pt) 2004-10-12 2017-03-30 Kyorin Seiyaku Kk Processo para a produção de cloridrato de 2-amino-2-[2-[4-(3- benziloxi-feniltio)-2-clorofenil[etil]-1,3-propanodiol
PT1932522E (pt) 2005-10-07 2012-06-26 Kyorin Seiyaku Kk Agente terapêutico para doenças do fígado contendo, como princípio activo, um derivado de 2- amino-1,3-propanodiol
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
CN101501049B (zh) 2006-08-08 2013-04-24 杏林制药株式会社 氨基磷酸酯衍生物以及将它们作为有效成分的s1p受体调节剂
NZ574012A (en) 2006-08-08 2012-02-24 Kyorin Seiyaku Kk Aminoalcohol derivative and immunosuppressant containing the same as active ingredient
JP5452237B2 (ja) * 2008-02-07 2014-03-26 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
BRPI0908638A2 (pt) * 2008-05-20 2015-10-06 Kyorin Seiyaku Kk agente para indução/manuntenção de remissão; método para manutenção da remissão induzida e uso de um agonista
EP2326621B1 (en) 2008-07-23 2016-06-08 Arena Pharmaceuticals, Inc. SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS
RS54970B1 (sr) 2008-08-27 2016-11-30 Arena Pharm Inc Supstituisani triciklični derivati kiselina kao s1p1 receptor agonisti korisni pri lečenju autoimunih i upalnih poremećaja
EP2177521A1 (en) 2008-10-14 2010-04-21 Almirall, S.A. New 2-Amidothiadiazole Derivatives
EP2364088B1 (en) * 2008-10-30 2014-04-16 Biogen Idec MA Inc. Bicyclic aryl sphingosine 1-phosphate analogs
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
EP2305660A1 (en) 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
EP2343287A1 (en) 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
EP3378854B1 (en) 2010-01-27 2022-12-21 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CA2789480A1 (en) 2010-03-03 2011-09-09 Arena Pharmaceuticals, Inc. Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
EP2366702A1 (en) 2010-03-18 2011-09-21 Almirall, S.A. New oxadiazole derivatives
EP2390252A1 (en) 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
EP2455081A1 (en) * 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of crohn's disease
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
KR101787543B1 (ko) 2014-08-22 2017-10-19 샘표식품 주식회사 발효배양 산삼을 포함하는 항염증 조성물
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
SI3310760T1 (sl) 2015-06-22 2023-02-28 Arena Pharmaceuticals, Inc. Kristalinična L-argininska sol (R)-2-(7-(4-ciklopentil-3-(trifluorometil)benziloksi)-1,2,3,4- tetrahidrociklo-penta(b)indol-3-il)ocetne kisline za uporabo pri motnjah, povezanih z receptorjem S1P1
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
MA47503A (fr) 2017-02-16 2021-04-21 Arena Pharm Inc Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales
AU2019311609A1 (en) 2018-07-27 2021-02-04 Priothera Limited Agent for inhibiting recurrence of hematological malignancy in patients who have undergone hematopoietic stem cell transplantation
US11555015B2 (en) 2018-09-06 2023-01-17 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE172711T1 (de) * 1992-10-21 1998-11-15 Yoshitomi Pharmaceutical 2-amino-1, 3- propandiolverbindung und immunosuppressium
US5948820A (en) * 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
DK1002792T3 (da) * 1997-04-04 2004-11-22 Mitsubishi Pharma Corp 2-aminopropan-1,3-diolforbindelser, medicinsk anvendelse deraf og mellemprodukter til syntese af disse
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
ES2284256T3 (es) * 1998-07-02 2007-11-01 Kyowa Hakko Kogyo Co., Ltd. Medicamentos para la diabetes.
AU767241B2 (en) * 1998-09-14 2003-11-06 Qiang Xu Immunosuppressive agents
US20020143034A1 (en) * 1998-12-30 2002-10-03 Fujisawa Pharmaceutical Co. Ltd. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
WO2001098301A1 (fr) 2000-06-20 2001-12-27 Japan Tobacco Inc. Composes de pyrazolopyridine et utilisation de ces derniers en tant que medicaments
WO2002006268A1 (fr) * 2000-07-13 2002-01-24 Sankyo Company, Limited Derives d'alcool amino
JP2002053575A (ja) 2000-08-09 2002-02-19 Sankyo Co Ltd アミノアルコ−ル類
AU2001285331B2 (en) * 2000-08-31 2006-04-06 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
DE60234092D1 (de) * 2001-01-30 2009-12-03 Univ Virginia Agonisten und antagonisten von sphingosin-1-phosphatrezeptoren
EP1364659B1 (en) * 2001-02-08 2009-11-11 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
CA2435739A1 (en) * 2001-02-22 2002-09-06 Novartis Ag Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
WO2002076995A2 (en) * 2001-03-26 2002-10-03 Novartis Ag 2-amino-propanol derivatives
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
JP4378597B2 (ja) * 2001-05-10 2009-12-09 小野薬品工業株式会社 カルボン酸誘導体化合物およびそれらを有効成分とする薬剤
US20040138462A1 (en) * 2001-05-24 2004-07-15 Minoru Sakurai Aminoalcohol derivatives
US20040235794A1 (en) * 2001-09-04 2004-11-25 Shinji Nakade Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
DE60235900D1 (de) * 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
CN1329372C (zh) * 2001-09-27 2007-08-01 杏林制药株式会社 二芳基硫醚衍生物及其加成盐和免疫抑制剂
JP4035759B2 (ja) 2001-11-06 2008-01-23 独立行政法人産業技術総合研究所 アミノアルコールリン酸化合物、製造方法、及びその利用方法
KR100836547B1 (ko) * 2002-01-11 2008-06-10 상꾜 가부시키가이샤 아미노 알코올 유도체 또는 포스폰산 유도체 및 이들을함유하는 의약 조성물
JP2003267936A (ja) 2002-01-11 2003-09-25 Sankyo Co Ltd ベンゼン環化合物
JP4430941B2 (ja) * 2002-01-18 2010-03-10 メルク エンド カムパニー インコーポレーテッド Ｅｄｇ受容体作動薬
US20040058894A1 (en) * 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
US7351725B2 (en) * 2002-01-18 2008-04-01 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
WO2003074008A2 (en) * 2002-03-01 2003-09-12 Merck & Co., Inc. Aminoalkylphosphonates and related compounds as edg receptor agonists
CA2477423A1 (en) * 2002-03-01 2003-09-12 Merck & Co., Inc. Aminoalkylphosphonates and related compounds as edg receptor agonists
EP1549640A4 (en) * 2002-06-17 2008-08-06 Merck & Co Inc 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) AZETIDINE-3-CARBOXYLATE AND 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) PYRROLIDIN-3-CARBOXYLATE AS EDG RECEPTOR AGONISTS
EP1522314B1 (en) * 2002-06-26 2014-03-05 Ono Pharmaceutical Co., Ltd. Remedies for diseases caused by vascular contraction or dilation
US7241790B2 (en) * 2002-07-30 2007-07-10 University Of Virginia Patent Foundation Compounds active in spinigosine 1-phosphate signaling
CN100516024C (zh) * 2002-09-13 2009-07-22 诺瓦提斯公司 氨基-丙醇衍生物
EP1548003A4 (en) * 2002-09-19 2006-06-07 Kyorin Seiyaku Kk AMINO ALCOHOL DERIVATIVE, ADDITIONAL SALT AND IMMUNOSUPPRESIVE AGENT
PL375053A1 (en) * 2002-09-24 2005-11-14 Novartis Ag Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
AU2003241836A1 (en) * 2002-10-03 2004-04-23 Ono Pharmaceutical Co., Ltd. Lpa receptor antagonists
JP4140698B2 (ja) 2002-10-18 2008-08-27 第一三共株式会社 リン酸又はホスホン酸誘導体
AU2003297232B2 (en) * 2002-12-20 2010-02-04 Merck Sharp & Dohme Corp. 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles
EP1594508B1 (en) * 2003-02-11 2012-08-08 Irm Llc Novel bicyclic compounds and compositions
CA2515574C (en) * 2003-02-18 2012-03-13 Kyorin Pharmaceutical Co., Ltd. Aminophosphonic acid derivative, salt thereof, and modulator of s1p receptor
EP2316431B1 (en) * 2003-04-08 2015-09-30 Novartis AG Solid oral composition comprising a S1P receptor agonist and a sugar alcohol
JP2004307441A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd ベンゼン誘導体とその付加塩及び免疫抑制剤
JP2004307439A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd アミノジオール誘導体とその付加塩及び免疫抑制剤
JP2004307440A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd ２−アミノ‐１，３‐プロパンジオール誘導体とその付加塩
JP2004307442A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd ヘテロ環誘導体とその付加塩及び免疫抑制剤
CN1777575B (zh) * 2003-04-30 2010-05-12 诺瓦提斯公司 作为1-磷酸-鞘氨醇受体调节剂的氨基-丙醇衍生物
CA2523677A1 (en) * 2003-04-30 2004-11-11 Novartis Ag Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
CA2524867A1 (en) * 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
CA2524054C (en) * 2003-05-19 2012-04-24 Irm Llc Immunosuppressant compounds and compositions
GB0313612D0 (en) * 2003-06-12 2003-07-16 Novartis Ag Organic compounds
JP2005047899A (ja) 2003-07-11 2005-02-24 Sankyo Co Ltd アミノアルコール化合物
WO2005014603A1 (en) 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Phosphinane compounds with immunomodulating activity
TW200505416A (en) 2003-08-12 2005-02-16 Mitsubishi Pharma Corp Bi-aryl compound having immunosuppressive activity
CA2535704C (en) * 2003-08-28 2012-12-11 Novartis Ag Aminopropanol derivatives
CN101407471A (zh) * 2003-08-29 2009-04-15 小野药品工业株式会社 能够结合s1p受体的化合物及其药物用途
US20070043014A1 (en) * 2003-10-01 2007-02-22 Merck & Co., Inc. 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
GB0324210D0 (en) * 2003-10-15 2003-11-19 Novartis Ag Organic compounds
US7638637B2 (en) * 2003-11-03 2009-12-29 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
WO2005058848A1 (en) * 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
TW200526548A (en) 2003-12-25 2005-08-16 Sankyo Co Ether derivatives
GB0401332D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
TW200538433A (en) * 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
WO2005079788A1 (ja) * 2004-02-24 2005-09-01 Sankyo Company, Limited アミノアルコール化合物
WO2005082841A1 (en) * 2004-02-24 2005-09-09 Irm Llc Immunosuppressant compounds and compositions
JP2005247691A (ja) 2004-03-01 2005-09-15 Toa Eiyo Ltd Ｓ１ｐ３受容体拮抗薬
GB0405289D0 (en) * 2004-03-09 2004-04-21 Novartis Ag Organic compounds
BRPI0510315A (pt) * 2004-04-30 2007-10-16 Chiron Srl integração de vacinação com conjugado meningocócico
AU2005237254B2 (en) * 2004-05-03 2010-02-04 Novartis Ag Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor
GB0411929D0 (en) * 2004-05-27 2004-06-30 Novartis Ag Organic compounds
JP5315611B2 (ja) * 2004-06-23 2013-10-16 小野薬品工業株式会社 Ｓ１ｐ受容体結合能を有する化合物およびその用途
PL1772145T3 (pl) * 2004-07-16 2011-08-31 Kyorin Seiyaku Kk Sposób skutecznego stosowania leku i sposób dotyczący zapobiegania efektom ubocznym
TW200611687A (en) * 2004-07-29 2006-04-16 Sankyo Co Pharmaceutical compositions used for immunosuppressant
RU2007109207A (ru) * 2004-08-13 2008-09-20 Прикис Фамэсьютикэлс, Инк. (US) Соединения-модуляторы активности рецептора сфингозин-1-фосфата (варианты), фармацевтическая композиция, содержащая указанные соединения, и способ лечения нарушения, ассоциированного со сфингозин-1-фосфатом
JPWO2006041015A1 (ja) 2004-10-12 2008-05-15 杏林製薬株式会社 アミノアルコール誘導体とその付加塩及び免疫抑制剤
PT2511262T (pt) * 2004-10-12 2017-03-30 Kyorin Seiyaku Kk Processo para a produção de cloridrato de 2-amino-2-[2-[4-(3- benziloxi-feniltio)-2-clorofenil[etil]-1,3-propanodiol
JP2008522977A (ja) 2004-12-06 2008-07-03 ユニバーシティ オブ バージニア パテント ファンデーション スフィンゴシン＝１−リン酸のアリールアミドアナログ
TW200702326A (en) 2005-05-31 2007-01-16 Mitsubishi Pharma Corp 2-aminobutanol compound and its pharmaceutical use
TWI418350B (zh) * 2005-06-24 2013-12-11 Sankyo Co 含有ｐｐａｒ調節劑之醫藥組成物的用途
PT2295049E (pt) * 2005-09-09 2015-03-02 Novartis Ag Tratamento de doenças auto-imunes
PT1932522E (pt) 2005-10-07 2012-06-26 Kyorin Seiyaku Kk Agente terapêutico para doenças do fígado contendo, como princípio activo, um derivado de 2- amino-1,3-propanodiol
JP5140854B2 (ja) 2005-10-12 2013-02-13 トーアエイヨー株式会社 Ｓ１ｐ３受容体拮抗剤
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
BRPI0714593A2 (pt) * 2006-07-25 2013-05-07 Alcon Res Ltd antagonistas de receptores da subfamÍlia 3 (edg-3, s1p3) do gene de diferenciaÇço endotelial para a prevenÇço e tratamento de doenÇas oculares, composiÇÕes compreendendo os referidos antagonistas, e usos dos mesmos
US7877152B2 (en) * 2006-07-31 2011-01-25 JusJas LLC Bipolar stimulation/recording device with widely spaced electrodes

Also Published As

Publication number Publication date
HK1126119A1 (en) 2009-08-28
JP5042042B2 (ja) 2012-10-03
BRPI0706971A2 (pt) 2011-09-27
EP1982708B1 (en) 2014-11-05
HRP20080421A2 (en) 2008-12-31
CA2641546A1 (en) 2007-08-16
EP1982708A1 (en) 2008-10-22
DK1982708T3 (en) 2014-12-01
EP1982708A4 (en) 2010-03-17
CY1116112T1 (el) 2017-02-08
KR20080096650A (ko) 2008-10-31
CN101378743A (zh) 2009-03-04
IL192150A (en) 2015-04-30
AU2007213194A1 (en) 2007-08-16
IL192150A0 (en) 2008-12-29
KR101334153B1 (ko) 2013-11-28
RU2008135264A (ru) 2010-03-20
US20090137685A1 (en) 2009-05-28
MA31338B1 (fr) 2010-05-03
CA2641546C (en) 2013-12-24
GT200800148A (es) 2008-10-29
ECSP088662A (es) 2008-09-29
HRP20080421B1 (hr) 2015-07-17
TW200806281A (en) 2008-02-01
ZA200806199B (en) 2009-04-29
EP2520291A1 (en) 2012-11-07
PT1982708E (pt) 2014-12-23
TWI389683B (zh) 2013-03-21
TNSN08246A1 (en) 2009-10-30
NO20082708L (no) 2008-09-02
CN101378743B (zh) 2014-05-28
AU2007213194B9 (en) 2013-05-16
PL1982708T3 (pl) 2015-03-31
RU2428976C2 (ru) 2011-09-20
SG169370A1 (en) 2011-03-30
AU2007213194B2 (en) 2013-03-14
MX2008008872A (es) 2008-10-23
NZ568907A (en) 2011-08-26
WO2007091501A1 (ja) 2007-08-16
MY151193A (en) 2014-04-30
JPWO2007091501A1 (ja) 2009-07-02
ES2524056T3 (es) 2014-12-03
US8318811B2 (en) 2012-11-27

Similar Documents

Publication Publication Date Title
ZA200806199B (en) Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3-propanaediol derivative as active ingredient, and method for treatment of inflammatory bowel disease
IL209282A (en) History of n-pipridine-3-yl-2-benzimidazole carboxamide and drugs containing it for the treatment of cardiovascular disease
EP1804813A4 (en) FORMULATIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
PL2371853T3 (pl) Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, kompozycja farmaceutyczna, zastosowanie pochodnej insuliny lub jej farmaceutycznie dopuszczalnej soli oraz sposób leczenia
IL176960A0 (en) Compositions and methods of treatment for inflammatory diseases
EP1920770A4 (en) THERAPEUTIC AGENT AGAINST INFLAMMATORY DISEASE AND TNF ALPHA PRODUCTION DISEASE
PL2001466T3 (pl) Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
EP1932522A4 (en) THERAPEUTIC AGENT FOR LIVER DISEASE CONTAINING 2-AMINO-1,3-PROPANEDIOL DERIVATIVE AS AN ACTIVE INGREDIENT AND ASSOCIATED THERAPEUTIC METHOD FOR LIVER DISEASE
IL197934A (en) History of hydrobenzamide as hsp90 inhibitors and their use in the treatment of disease
IL201189A (en) Fluorization derivatifrone derivatives used as iron pellets in the treatment of neurodegenerative diseases, their preparation and their pharmaceutical preparations
IL196202A0 (en) Indazole derivatives for the treatment of hsp90-induced diseases
PT1828151E (pt) Derivados de malonamida como inibidores de gama-secretase para o tratamento da doença de alzheimer
EP2142549A4 (en) ADENOSINE DERIVATIVES, METHODS OF THEIR SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES THEREOF CONTAINING THEM AS AN ACTIVE SUBSTANCE
EP1915998A4 (en) PROPHYLACTIC OR THERAPEUTIC AGENT FOR CORNEAL OR CONJUNCTIVAL DISEASE
HK1141708A1 (en) Agent for treatment of pulmonary disease
IL201418A0 (en) Therapeutic agent for glaucoma containing adenosine derivative as active ingredient
EP2099446A4 (en) METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASE
EP1948210A4 (en) METHOD FOR TREATING ISCHEMIC HEART DISEASE
EP2098228A4 (en) ANTI-INFLAMMATORY AGENT CONTAINING 2-AMINOPHENOL OR A DERIVATIVE THEREOF AS ACTIVE INGREDIENT
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
IL194066A0 (en) Therapeutic composition for treatment of tinnitus
EP2077847A4 (en) DI- AND ALKYL AND HALOGENATED TRISACCHARIDES AND PHARMACEUTICAL PREPARATIONS, DIAGNOSTIC KITS AND METHODS FOR TREATMENT THEREOF
ZA200704684B (en) Therapeutic antisense oligonucleotide composition for the treatment of inflammatory bowel disease
EP1967208A4 (en) THERAPEUTIC AGENT FOR SKIN OR AGENT PROMOTING REGENERATION OF SKIN CONTAINING GHRELINE, AND DERIVATIVES THEREOF OR SUBSTANCE CAPABLE OF ACTING AS ACTIVE INGREDIENT ON GHS-R1a
EP1967201A4 (en) THERAPEUTIC AGENT FOR SKIN OR SKIN REGENERATING AGENT CONTAINING DESACYL-GHRELINE OR A DERIVATIVE THEREOF AS ACTIVE INGREDIENT